Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
MYCOSTATIN ORAL TABLETS SCHEDULING STATUS: S4 PP ZIMBABWE ONLY PROPRIETARY NAME (and dosage form): MYCOSTATIN ORAL TABLETS COMPOSITION MYCOSTATIN ORAL TABLETS each contain 500 000 units nystatin . PHARMACOLOGICAL CLASSIFICATION Category A 20.1.7 Antifungal antibiotics. PHARMACOLOGICAL ACTION Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. Nystatin is an antibiotic with antifungal activity against a wide variety of yeasts and yeast-like fungi. The antifungal activity of nystatin is at least in part dependent on its binding to a sterol moiety, primarily ergosterol, present in the membrane of sensitive fungi, which results in an increase in the permeability of the membrane and leakage of intra- cellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa or viruses. INDICATIONS MYCOSTATIN ORAL TABLETS are indicated for the treatment of intestinal candidiasis. CONTRA-INDICATIONS Patients with a history of hypersensitivity to any component. Pregnancy and Lactation Safety of use during pregnancy has not been established. It is not known whether nystatin is excreted in human milk. DOSAGE AND DIRECTIONS FOR USE The usual dose is one tablet (500 000 units) three times daily. This dosage may be increased to two tablets (1 000 000 units) three times daily if intestinal fungi are not adequately suppressed. The treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse. SIDE EFFECTS AND SPECIAL PRECAUTIONS Nystatin may produce diarrhoea and gastro-intestinal disturbance, nausea and vomiting. Rash, including urticaria, has been reported. Stevens-Johnson syndrome has been reported very rarely. MYCOSTATIN ORAL TABLETS should not be used for the treatme Read the complete document